The aim of the present study was to compare the effects of selective phosphodiesterase (PDE) 3, 4 and 5 inhibitors on antigen-induced airway hyperresponsiveness in sensitized guinea-pigs. When the sensitized guinea-pigs were orally pre-treated with the selective PDE4 inhibitor, Ro 20–1724 (30 mg/kg), and studied 48 h after OA, a significant reduction ($P<0.01$) of the leftward shift of the dose–response curve to ACh was noted, whereas it was ineffective at the lower dose (10 mg/kg). Administration of the selective PDE3 inhibitor, milrinone (30 mg/kg) also elicited a significant reduction ($P<0.01$) of the airway hyperresponsiveness, whereas the PDE5 inhibitor zaprinast (30 mg/kg) was ineffective. These results show that both PDE3 and PDE4 inhibitors are able to inhibit the antigen-induced airway hyperresponsiveness in sensitized guinea-pigs and support the potential utility of selective PDE inhibitors in the treatment of asthma.

Key words: Selective phosphodiesterase inhibitor, Guinea-pig, Airway hyperresponsiveness

Introduction

Bronchial asthma is a disease characterized by variable airway obstruction and airway hyperresponsiveness that has been linked to mucosal inflammation and particularly, the influx and activation of eosinophils. One way to reduce the development of airway hyperresponsiveness is to inhibit the associated inflammation by anti-inflammatory drugs. However, under certain conditions, airway hyperresponsiveness has been observed despite the absence of any inflammatory process, such as eosinophil recruitment. We have previously demonstrated that substance P is able to induce airway hyperresponsiveness not associated with eosinophil recruitment, but with an enhancement of alveolar macrophage activation.

The cyclic nucleotides, cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP), are important second messengers of cellular function. Phosphodiesterases (PDEs) are a group of enzymes that regulate the breakdown of cyclic nucleotides. Among PDEs, PDE3 and PDE4 appear to be the most important for the regulation of cyclic AMP, whereas PDE5 is responsible for the level of intracellular cGMP. As far as anti-inflammatory drugs are concerned, much attention has been focused on the therapeutic potential of selective PDE4 inhibitors (for review see Refs 3 and 4). It has also been frequently reported that PDE3 inhibitors do not have potent anti-inflammatory effects. This has been clearly demonstrated on eosinophil recruitment induced by antigen challenge, PAF aerosol exposure or intratracheal administration of IL-5. This is probably due to the fact that in most inflammatory cells, including eosinophils, the low $K_m$ cyclic AMP-specific members of the PDE4 family are the most prominently expressed. However, in mononuclear cells, PDE3 is also involved in the regulation of cyclic AMP levels. In macrophages, in the presence of the adenylyl cyclase activator, PGE$_2$, PDE3 inhibitors are as effective as PDE4-selective drugs in inhibiting TNF-α release. We also recently demonstrated that PDE3 and PDE4 isoenzymes are present in alveolar macrophages from sensitized guinea-pigs and that PDE4, but also PDE3, regulate the release of inflammatory mediators.

Numerous studies have reported the actual efficacy of PDE inhibitors, namely selective PDE4 inhibitors, on the development of airway hyperresponsiveness. However the effects of PDE3 inhibitors appear controversial. The present study was undertaken in order to compare the effect of milrinone, a selective PDE3 inhibitor, Ro 20–1724, a selective PDE4 inhibitor, and zaprinast, a selective PDE5 inhibitor, on the development of airway hyperresponsiveness in sensitized and challenged guinea-pigs.
Methods

Materials

The following drugs were used: ovalbumin (OA, chicken egg, grade V) and milrinone (Sigma, St. Louis, MO, USA), Ro 20–1724 (RBI, Natick, MA, USA), urethane (ethylocarbamate, Prolabo, Paris, France), pancuronium bromide (Pavulon, Organon, Fresnes, France). Racemic rolipram was synthesized at the Institut de Recherche Jouvenal/Parke-Davis, Fresnes, France. Zaprinast was a generous gift of Rhône-Poulenc Rorer (UK).

Sensitization procedure and challenge

Specific pathogen-free male Hartley guinea-pigs (300–350 g, Charles River, St. Aubin les Elboeuf, France) were used throughout the study. Following purchase, they were housed in our standard animal care facilities. All guinea-pigs were fed standard pellet (UAR, Villemoisson-sur-Orge, France) and given water ad libitum. Guinea-pigs were sensitized and challenged as previously described. Briefly, they were placed in a Plexiglas chamber (30 x 50 x 30 cm) and exposed twice for 30 min to an aerosol of ovalbumin (OA) 2 mg/ml in saline (NaCl, 0.9 %), with a 48-h interval. The aerosol was generated by a Devilbiss ultrasonic nebulizer (Aerodynamic mean mass median particle diameter of 0.5–5 μM, ULTRA-NEB 99, Somerset, PA, USA). Fifteen to 20 days after the initial sensitization procedure, the guinea-pigs were challenged by 15-min exposures to five successive solutions of OA of respectively 10 μg/ml, 100 μg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml. Control guinea-pigs were exposed to a saline solution for an equivalent period of time.

Assessment of airway hyperresponsiveness

Bronchopulmonary reactivity to acetylcholine was assessed 48 h after antigen challenge or saline exposure. Guinea-pigs are anesthetized (urethane, 1.2 g/kg, i.p.) and placed in a dorsal recumbent position. A tracheal cannula was inserted and the lungs were mechanically ventilated with a constant tidal volume (1 ml laboratory air/100 g body weight) with a respiratory pump (Ugo Basile, Varese, Italy, 60 breaths/min). Spontaneous breathing was abolished with pancuronium bromide (2 mg/kg), injected in the posterior penis vein. Airway inflation pressure (AIP), an index of intrathoracic airway caliber, was monitored from a lateral port of the ventilator circuit using a Ugo basile bronchospasm transducer according to the previously described method.

After a 10-min equilibration period, three successive 1-min aerosol administrations of Ach (50, 100, 200 and 500 μg/ml) were performed at 10-min intervals with constant monitoring of the airway inflation pressure. The aerosol was generated by a Devilbiss 'Pulmosonic' ultrasonic nebulizer permanently connected in series with the afferent limb of the ventilator circuit. The airway inflation pressure was expressed as percent change over the 100% obtained by clamping the tracheal cannula at the end of the experiment.

Protocol

All drugs were prepared extemporaneously in distilled water containing 5% Arabic gum. Sensitized guinea-pigs were treated orally with either Ro 20–1724 (10 or 30 mg/kg) or milrinone (30 mg/kg) or zaprinast (30 mg/kg), 24 and 3 h before the antigen challenge or saline exposure.

Data analysis

Results are expressed as means±SEM. Statistical differences between the dose-responses to Ach in the groups receiving the various treatment were analyzed by two-way analysis of variance. It was thus possible to examine the whole dose–response curves obtained in these different groups of animals.

Results

Exposure of anaesthetized guinea-pigs to the successive aerosols of ACh (50, 100, 200 and 500 μg/ml) induced a dose-related bronchopulmonary response. When the animals were previously exposed to OA, the dose–response curve to ACh was significantly shifted to the left (P<0.001) (Figs 1–4). When the sensitized guinea-pigs were pretreated with Ro 20–1724 (30 mg/kg), and studied 48 h after OA, a significant reduction (P<0.05) of the leftward shift of the dose–response curve to ACh was noted (Fig. 1), whereas no effect was observed at the lower dose (10 mg/kg) (Fig. 2). Administration of milrinone (30 mg/kg) also elicited a significant reduction (P<0.05) of the leftward shift of the dose–response curve to ACh after OA challenge (Fig. 3), whereas, zaprinast (30 mg/kg) had no effect (Fig. 4).

Discussion

The present study demonstrated that the selective PDE4 inhibitor, Ro 20–1724 and the selective PDE3 inhibitor, milrinone, but not the selective PDE5 inhibitor, zaprinast, are able to inhibit the development of airway hyperresponsiveness induced by antigen challenge in sensitized guinea-pigs. Airway hyperresponsiveness induced by antigen challenge is generally associated in humans and in experimental animals with an influx of inflammatory cells in lung tissue and the activation of resident

N. Germain et al.
pulmonary cells such as alveolar macrophages.\textsuperscript{9,17,18} We have also reported that macrophages recovered in the BAL fluid of either saline-exposed or OA-challenged sensitized guinea-pigs exhibit a PDE type 3 and a PDE type 4 isoenzyme activity.\textsuperscript{9} It can therefore be suggested that the profile of PDE activities in macrophages may influence the activity of PDE inhibitors. In this regard, we observed that the combination of milrinone and the selective PDE4 inhibitors, rolipram or Ro 20–1724 had a significant inhibitory effect on arachidonate release.\textsuperscript{9} We recently proposed that the reduced activity of alveolar macrophages may be involved in the inhibition of the development of airway hyperresponsiveness by both PDE3 and PDE4 inhibitors and suggest that activation of alveolar macrophages is a key event in the bronchopulmonary alterations that follow antigen challenge.

Such a hypothesis is not consistent with the fact that the development of airway hyperresponsiveness is closely associated with eosinophil influx in airways. We and others have previously demonstrated that PDE4 inhibitors, but not PDE3 inhibitors, are able to reduce the eosinophil recruitment induced either by antigen challenge in sensitized guinea-pigs\textsuperscript{5,19} or administration of chemotactic factor, such as PAF and IL-5 in naive guinea-pigs.\textsuperscript{8,6} This would suggest a dissociation between eosinophil recruitment and the development of airway hyperresponsiveness. This dissociation takes into account the fact that eosinophils do not contain PDE3 isoenzyme,\textsuperscript{4} and then that PDE3 inhibitors are not able to block mediator release from these inflammatory cells.\textsuperscript{19} This hypothesis is also strengthened by the results obtained with aerosol exposure of guinea-pigs to substance P. Indeed, the development of airway hyperresponsiveness induced by aerosol administration of substance P is associated with alveolar macrophage activation rather than granulocyte recruitment.\textsuperscript{7} A proposed mechanism for the inhibition of antigen-induced airway hyperresponsiveness by PDE inhibitors is the regulation of cyclic AMP by PDE3 and 4 contributing to the modulation of neuronal sensitivity in the airways and of tachykinin release.\textsuperscript{20,21}

It is now generally accepted that selective PDE4 inhibitors are able to reduce airway hyperresponsiveness, and that this effect is associated with anti-
inflammatory activities.\textsuperscript{10–12,21} However, recent studies have reported the effects of two PDE3 inhibitors. Using cilostazol, Uno and colleagues\textsuperscript{15} have reported an inhibition of LPS-induced bronchial hyperreactivity in guinea-pigs, and Fujimura \textit{et al.}\textsuperscript{13} a reduced bronchial hyperresponsiveness in asthmatic patients. Finally, Bardin \textit{et al.}\textsuperscript{14} have reported that the selective PDE3 inhibitor, MKS492, is able to prevent early bronchoconstrictor response in asthma and attenuates late response.

Since PDE3 inhibitors have bronchodilator and bronchoprotective properties,\textsuperscript{22} it can also be suggested that the bronchoprotective effect observed in these latter studies was due to their relaxant activity on smooth muscles.\textsuperscript{23} In the present study, we excluded such a possibility since the bronchopulmonary response induced by acetylcholine was not modified by milrinone in unchallenged animals.

In conclusion, the present study showed that PDE3 (milrinone) and PDE4 inhibitors (Ro 20–1724), but not the PDE5 inhibitor (zaprinast), are able to reduce the development of airway hyperresponsiveness in sensitized guinea-pigs and suggests that this group of selective compounds may have a role to play in the treatment of asthma.

ACKNOWLEDGEMENTS. The authors thank Guy Bouèr for his assistance in preparing the manuscript.

References

1. Holgate ST, Djukanovic R, Wilson J, Roche W, Roche PH, Howarth PH. Inflammatory processes and bronchial hyperresponsiveness. \textit{Clin Exp Allergy} 1991; 21 (Suppl 1): 30–36.
2. Boichert E, Lagente V, Paubert-Braquet M, Frossard N. Inhaled substance P induces activation of alveolar macrophages and increases airway responses in the guinea-pig. \textit{Neuropeptides} 1993; 25: 307–313.
3. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? \textit{Trends Pharmacol Sci} 1997; 18: 164–171.
4. Torphy TJ. Phosphodiesterase isozymes. Molecular targets for novel antiallergy agents. \textit{Am J Respir Crit Care Med} 1998; 157: 351–370.
5. Lagente V, Moodley I, Perrin S, Motrin G, Junien JL. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. \textit{Am J Respir Crit Care Med} 1997; 155: 1334–1339.
10. Howell RE, Sickels BD, Woeppel SL. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea-pigs. *J Pharmacol Exp Ther* 1993; 264: 609–615.

11. Ortiz JL, Valles JM, Marti-Cabrera M, Cortijo J, Morcillo EJ. Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation and microvascular leakage in guinea-pigs. *Naunyn Schmiedebergs Arch Pharmacol* 1996; 353: 200–206.

12. Danahay H, Broadley KJ. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration. *Br J Pharmacol* 1997; 120: 289–297.

13. Fujimura M, Kamio Y, Myou S, Hashimoto T, Matsuda T. Effect of phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma. *Int Arch Allergy Immunol* 1997; 114: 379–384.

14. Bardin PG, Dorward MA, Lampe FC, Franke B, Holgate ST. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. *Br J Clin Pharmacol* 1998; 45: 387–391.

15. Uno T, Tanaka H, Nagai H. Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea-pigs. *Gen Pharmacol* 1998, 30: 167–173.

16. Boichot E, Lagente V, Carre C, Walmann P, Mencia-Huerta JM, Braquet P. Bronchial hyperresponsiveness and cellular infiltration in the lung of guinea-pigs sensitized and challenged by aerosol. *Clin Exp Allergy* 1991; 21: 67–76.

17. Tonnell AB, Gosset P, Joseph M, Fournier E, Capron A. Stimulation of alveolar macrophages in asthmatic patients after local provocation tests. *Lancet* 1983; i: 1406–1408.

18. Lagente V, Boichot E, Chadi L, Dugas B, Mencia-Huerta JM, Braquet P. Effect of the platelet-activating factor antagonist, BN 50750, on the increased production of superoxide anions by alveolar macrophages from antigen-exposed sensitized guinea-pigs. *Fund Clin Pharmacol* 1991; 5: 426.

19. Banner KH, Page CR. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. *Eur Respir J* 1995; 8: 896–1000.

20. Spiro D, Harrison S, Page CP. Regulation by phosphodiesterase iso-enzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. *Br J Pharmacol* 1995; 116: 2334–2340.

21. Holbrook M, Gozzard N, James T, Higgs G, Hughes B. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP 840, a novel phosphodiesterase type 4 inhibitor. *Br J Pharmacol* 1996; 118: 1192–1200.

22. Rabe KE, Tenor H, Dent G, Schudt C, Liebig S, Magnusen H. Phosphodiesterase iso-enzymes modulating inherent tone in human airways: identification and characterization. *Am J Physiol* 1993; 264: L158–L164.

23. Planquais JM, Ruffin-Morin Y, Lagente V, Payne AN and Dahl SG. Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea-pig isolated trachea. *Fund Clin Pharmacol* 1996; 10: 356–367.

Received 11 February 1999; accepted in revised form 31 March 1999.